GT Biopharma, Inc.

GTBP

US36254L3087

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.345 ^USD	-10.84%		-9.35%	-56.27%

Mar. 26	GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 01	GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	MT

GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 26, 2024 at 05:01 pm EDT

GT Biopharma, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 7.6 million compared to USD 20.88 million a year ago. Basic loss per share from continuing operations was USD 5.64 compared to USD 19.66 a year ago.

Latest news about GT Biopharma, Inc.

GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	Feb. 01	MT
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	Dec. 04	CI
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting	Nov. 06	CI
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Index	23-06-23	CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Growth Index	23-06-23	CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell 3000E Growth Index	23-06-23	CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell 3000E Index	23-06-23	CI
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
North American Morning Briefing : Hopes Build for -3-	23-05-15	DJ
GT Biopharma, Inc. Announces Board Changes	23-05-04	CI
Certain Warrants of GT Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 5-APR-2023.	23-04-04	CI
Certain Common Stock of GT Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 5-APR-2023.	23-04-04	CI
North American Morning Briefing : Traders Await -3-	23-03-31	DJ
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
North American Morning Briefing : Stock Futures -2-	23-03-24	DJ
Beyond Air Affiliate Beyond Cancer Names Gavin Choy Chief Operating Officer	23-01-30	MT
EF Hutton Starts GT Biopharma at Hold With $2 Price Target	23-01-05	MT
GT Biopharma to Sell 6.5 Million Shares and Warrants, Expects Gross Proceeds of $6.5 Million	22-12-30	MT
Gt Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer	22-12-14	CI
GT Biopharma, Inc. Announces Gregory Berk, President of Research & Development and Chief Medical Officer, Is no Longer Employee	22-12-13	CI
GT Biopharma, Fate Therapeutics Say Preclinical Data Shows Potential of New Approach to Treat Leukemia	22-12-12	MT
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-31	CI

Chart GT Biopharma, Inc.

Duration

Period

More charts

Company Profile

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. Its TriKE platform generates therapeutics designed to harness and enhance the cancer killing abilities of a patientâs own natural killer (NK) cells. The Company is also using its TriKE platform to develop therapeutics useful for the treatment of infectious disease such as for the treatment of patients infected by the human immunodeficiency virus (HIV). Its GTB-3550 is the first-generation TriKE product candidate which was a single-chain, tri-specific recombinant fusion protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15, all connected by small peptide linkers.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.345 USD

Average target price

150 USD

Spread / Average Target

+4,384.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GT BIOPHARMA, INC.	-56.27%	4.62M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

GT Biopharma, Inc.

Equities

GTBP

US36254L3087

Pharmaceuticals

GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

Latest news about GT Biopharma, Inc.

Chart GT Biopharma, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals